5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Carcinoma
KRAS G12C Mutation
Unresectable Colorectal Cancer

Interventions

DRUG: Administration of experimental treatment association (sotorasib, panitumumab 5FU)

Sponsor

Federation Francophone de Cancerologie Digestive

Collaborators

[object Object]
[object Object]
[object Object]